Long-Term Aesthetic Efficacy and Safety of Liquid RelabotulinumtoxinA for Glabellar Lines: A 12-Month Randomized Controlled Trial

Long-Term Aesthetic Efficacy and Safety of Liquid RelabotulinumtoxinA for Glabellar Lines: A 12-Month Randomized Controlled Trial

Highlight

This 12-month, double-blind, phase 3b randomized controlled study evaluated the aesthetic efficacy and safety of a novel, ready-to-use liquid formulation of RelabotulinumtoxinA (relaBoNT-A) for treating glabellar lines (GLs). Key findings include rapid onset of effect—felt in nearly 40% of treated patients within one day—and durable improvement persisting through 6 months for most subjects and up to 12 months for some. Subjects receiving relaBoNT-A showed significantly higher aesthetic improvement at one month compared to placebo with high subject and investigator satisfaction. The treatment was well tolerated, with only mild treatment-related adverse events in 8.1% of patients.

Study Background

Glabellar lines, or the wrinkles that form between the eyebrows, are a common focal area in aesthetic dermatology due to their prominence in facial expression and aging. Botulinum toxin type A (BoNT-A) has become the gold standard for minimally invasive correction of dynamic facial lines, including glabellar lines, effectively reducing muscle contraction and thereby softening wrinkles. However, conventional BoNT-A treatments often require reconstitution and preparation, which can introduce variability in dosing and patient experience. RelabotulinumtoxinA (relaBoNT-A) represents an innovative, complex-free, ready-to-use liquid BoNT-A formulation designed to improve dosing consistency and ease of use, which may translate to more predictable aesthetic outcomes and consumer satisfaction.

Study Design

This was a multicenter, randomized, double-blind, placebo-controlled phase 3b trial designed to evaluate long-term efficacy, onset, patient and investigator satisfaction, and safety of relaBoNT-A in subjects with moderate-to-severe glabellar lines at maximum frown. The study randomized participants in a 3:1 ratio to receive a single intramuscular injection of 50 units of relaBoNT-A or placebo. Primary efficacy outcome was the subject-reported Global Aesthetic Improvement Scale (GAIS) responder rate at maximum frown at one month post-injection. Secondary outcomes included investigator-assessed glabellar line severity improvements (GL-ILA), onset of effect, subject satisfaction up to 12 months, and safety assessments throughout the study period.

Key Findings

At one month following injection, the proportion of subjects reporting aesthetic improvement (GAIS responder rate) was significantly higher in the relaBoNT-A group (92.9%) than in the placebo group (9.1%) with a p-value <0.001, underscoring a robust treatment effect. The investigator-assessed ≥1-grade improvement in glabellar line severity at maximum frown was observed in 57.4% of relaBoNT-A-treated subjects at six months, 28.1% at nine months, and 12.2% at 12 months, indicating sustained efficacy beyond the typical three to four months seen with conventional BoNT-A treatments.

Onset of effect was rapid, with investigators noting improvements in 43.9% of treated subjects and subject self-reports indicating improvement in 39.8% within one day after injection. High levels of injector confidence in dosing consistency were reported with the ready-to-use solution compared to placebo injections at baseline (98.0% vs. 100%) and maintained at Month 1 (99.0% vs. 64.5%). The natural appearance of results was also rated more favorably for relaBoNT-A versus placebo (98.0% vs. 64.5% at Month 1).

Subject satisfaction was consistently higher for relaBoNT-A than placebo from Day 1 through 12 months, with approximately two-thirds of relaBoNT-A recipients preferring this treatment to their prior powder formulation BoNT-A experiences. Safety analysis demonstrated that treatment-related adverse events were infrequent (8.1%) and mild, confirming the favorable safety profile of relaBoNT-A over a year-long monitoring period.

Expert Commentary

This study provides evidence supporting the clinical advantages of a ready-to-use liquid formulation of BoNT-A for aesthetic treatment of glabellar lines, particularly its rapid onset and prolonged duration of effect, which may translate to extended intervals between treatments and improved patient adherence. The enhanced dosing consistency reported by injectors is an important factor likely contributing to more predictable aesthetic outcomes and patient satisfaction. However, some limitations should be considered, including the single-dose design and the predominance of relatively mild adverse events which require longer surveillance to fully characterize safety over multiple treatment cycles.

Mechanistically, the lack of complexing proteins in relaBoNT-A may reduce immunogenic potential, although comparative immunologic studies were not addressed in this trial. Considering the sustained effect observed in some participants beyond six months, further research is warranted to evaluate the pharmacodynamics and optimal re-treatment intervals for this novel formulation.

Conclusion

RelabotulinumtoxinA in a ready-to-use liquid format demonstrates substantial and durable aesthetic improvement for glabellar lines with rapid onset and a favorable safety profile over 12 months. This formulation appears to offer practical advantages for both injectors and patients, including consistent dosing and natural-looking results, making it a promising addition to the armamentarium of aesthetic treatments for dynamic facial lines.

Funding and ClinicalTrials.gov

The study was supported by the manufacturer of RelabotulinumtoxinA. Specific funding details and trial registration numbers were not provided in the source abstract. Further information can be sought from the full text or clinical trial registries.

References

Schlessinger J, Kaufman-Janette J, Moradi A, Ablon GR, Cho YR, Cox SE, Weiss RA, Lain E, Hartman CL, Weinberg FA, Seisdedos Hedman D, Coquis-Knezek SF. Aesthetic Improvement of Glabellar Lines with Liquid RelabotulinumtoxinA Treatment in a 12-Month Randomized Controlled Study. Plast Reconstr Surg. 2026 Nov 10. PMID: 43012872. Available at: https://pubmed.ncbi.nlm.nih.gov/43012872/.

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply